TY - JOUR
T1 - Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk
T2 - Results from the EPIC cohort, plus a meta-analysis of prospective studies
AU - Rinaldi, Sabina
AU - Cleveland, Rebecca
AU - Norat, Teresa
AU - Biessy, Carine
AU - Rohrmann, Sabine
AU - Linseisen, Jakob
AU - Boeing, Heiner
AU - Pischon, Tobias
AU - Panico, Salvatore
AU - Agnoli, Claudia
AU - Palli, Domenico
AU - Tumino, Rosario
AU - Vineis, Paolo
AU - Peeters, Petra H.M.
AU - Van Gils, Carla H.
AU - Bueno-de-Mesquita, Bas H.
AU - Vrieling, Alina
AU - Allen, Naomi E.
AU - Roddam, Andrew
AU - Bingham, Sheila
AU - Khaw, Kay Tee
AU - Manjer, Jonas
AU - Borgquist, Signe
AU - Dumeaux, Vanessa
AU - Gram, Inger Torhild
AU - Lund, Eiliv
AU - Trichopoulou, Antonia
AU - Makrygiannis, Georgios
AU - Benetou, Vassiliki
AU - Molina, Esther
AU - Suárez, Ignacio Donate
AU - Gurrea, Aurelio Barricarte
AU - Gonzalez, Carlos A.
AU - Tormo, Maria Jose
AU - Altzibar, Jone M.
AU - Olsen, Anja
AU - Tjonneland, Anne
AU - Grønbæk, Henning
AU - Overvad, Kim
AU - Clavel-Chapelon, Françoise
AU - Boutron-Ruault, Marie Christine
AU - Morois, Sophie
AU - Slimani, Nadia
AU - Boffetta, Paolo
AU - Jenab, Mazda
AU - Riboli, Elio
AU - Kaaks, Rudolf
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Several prospective studies have shown a moderate positive association between increasing circulating insulin-like growth factor-I (IGF-I) levels and colorectal cancer risk. However, the associations were often statistically nonsignificant, and the relationship of cancer risk with IGF-I's major binding protein, IGFBP-3, showed major discrepancies between studies. We investigated the association of colorectal cancer risk with serum IGF-I, total and intact IGFBP-3, in a case-control study nested within the EPIC cohort (1,121 cases of colorectal cancer and 1,121 matched controls). Conditional logistic regression was used to adjust for possible confounders. Our present study results were combined in a meta-analysis with those from 9 previous prospective studies to examine the overall evidence for a relationship of prediagnostic serum IGF-I with colorectal cancer risk. In the EPIC study, serum concentrations of IGF-I and IGFBP-3 showed no associations with risk of colorectal cancer overall. Only in subgroup analyses did our study show moderate positive associations of IGF-I levels with risk, either among younger participants only (and only for colon cancer) or among participants whose milk intakes were in the lowest tertile of the population distribution (RR for an increase of 100 ng/ml = 1.43 [95% CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive association remained between serum IGF-I and colorectal cancer risk overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in IGF-I). Overall, data from our present study and previous prospective studies combined indicate a relatively modest association of colorectal cancer risk with serum IGF-I.
AB - Several prospective studies have shown a moderate positive association between increasing circulating insulin-like growth factor-I (IGF-I) levels and colorectal cancer risk. However, the associations were often statistically nonsignificant, and the relationship of cancer risk with IGF-I's major binding protein, IGFBP-3, showed major discrepancies between studies. We investigated the association of colorectal cancer risk with serum IGF-I, total and intact IGFBP-3, in a case-control study nested within the EPIC cohort (1,121 cases of colorectal cancer and 1,121 matched controls). Conditional logistic regression was used to adjust for possible confounders. Our present study results were combined in a meta-analysis with those from 9 previous prospective studies to examine the overall evidence for a relationship of prediagnostic serum IGF-I with colorectal cancer risk. In the EPIC study, serum concentrations of IGF-I and IGFBP-3 showed no associations with risk of colorectal cancer overall. Only in subgroup analyses did our study show moderate positive associations of IGF-I levels with risk, either among younger participants only (and only for colon cancer) or among participants whose milk intakes were in the lowest tertile of the population distribution (RR for an increase of 100 ng/ml = 1.43 [95% CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive association remained between serum IGF-I and colorectal cancer risk overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in IGF-I). Overall, data from our present study and previous prospective studies combined indicate a relatively modest association of colorectal cancer risk with serum IGF-I.
KW - Colorectal neoplasms
KW - European Prospective Investigation into Cancer (EPIC)
KW - Insulin-like growth factor-i (IGF-I)
KW - Meta-analysis
KW - Nested case control study
UR - https://www.scopus.com/pages/publications/77449111832
U2 - 10.1002/ijc.24927
DO - 10.1002/ijc.24927
M3 - Article
C2 - 19810099
AN - SCOPUS:77449111832
SN - 0020-7136
VL - 126
SP - 1702
EP - 1715
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 7
ER -